Oral miltefosine for the treatment of Indian visceral leishmaniasis.

  title={Oral miltefosine for the treatment of Indian visceral leishmaniasis.},
  author={Shyam Sundar and Tara Kant Jha and Chandreshwar Prasad Thakur and Sujit Kumar Bhattacharya and Madhukar Rai},
  journal={Transactions of the Royal Society of Tropical Medicine and Hygiene},
  volume={100 Suppl 1},

Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.

  • E. Palumbo
  • Medicine, Biology
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • 2008
Miltefosine, a phosphocholine analogue originally developed as antimalignant drug, has been found to be highly active against Leishmania in vitro and in animal model and was tried against human visceral leishmaniasis and found to been highly effective in children.

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis

ABSTRACT An open-label pharmacokinetics (PK) clinical trial was conducted to comparatively assess the PK and explore the pharmacodynamics (PD) of miltefosine in children and adults with cutaneous

Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis

The data demonstrate that the miltefosine drug, at the recommended dose and treatment regime, was safe and efficacious for the treatment of canine leishmaniosis.

Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.

Strategies to prevent the development and spread of miltefosine resistance are urgently needed and Appropriate regimens for New World mucocutaneous leishmaniasis need to be established, although longer treatment duration seems to confer better results.

Treatment of Visceral Leishmaniasis

This chapter provides a review on the treatment of VL and gives therapeutic options with the grade of recommendation according to the Leishmania implicated and the geographical location of the infection.

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

This study is the first evidence on its clinical efficacy in Leishmania (Viannia) guyanensis, and miltefosine was safe and relatively well tolerated and cure rate was higher than antimony.

Development of miltefosine as an oral treatment for leishmaniasis.

  • H. SindermannJ. Engel
  • Biology, Medicine
    Transactions of the Royal Society of Tropical Medicine and Hygiene
  • 2006

Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field

The main findings associated with miltefosine susceptibility and resistance in Leishmania are described: two important factors involved in efficacy and failure in leishmaniasis treatment using this drug.

The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia – A review and meta-analysis

It is considered to halt the use of MF monotherapy for PKDL patients in India with the caveat that the efficacy has recently been observed to decline, and the provision of safer treatment regimens for PK DL patients are recommended.

In Vivo Antileishmanial Efficacy of Miltefosine Against Leishmania (Leishmania) amazonensis

It is demonstrated that MF is an effective and safe therapeutic alternative for leishmaniasis by L. (L.) amazonensis and is more efficacious than MA.



Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.

It is indicated that miltefosine is as effective and well tolerated in Indian children with VL as in adults and that it can be recommended as the first choice for treatment of childhood VL in India.

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

Oral miltefosine was safe and ∼90% effective in this initial clinical trial of childhood visceral leishmaniasis, and well-tolerated.

Oral treatment of visceral leishmaniasis with miltefosine.

Results indicate that 100 mg miltefosine/day for 28 days is a promising oral-treatment regimen for VL cases, including those with antimony-unresponsive infections.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Orally administered miltefosine appears to be an effective treatment for Indian visceral leishmaniasis.

Oral miltefosine for Indian visceral leishmaniasis.

Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis and may also be helpful in regions where parasites are resistant to current agents.

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

AMB appears far superior to SAG as a first-line drug against VL and should replace it, according to the setting of the present study.

Short-course of oral miltefosine for treatment of visceral leishmaniasis.

  • S. SundarA. Makharia H. Murray
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days, 21 days, or 28 days, and cure was achieved in 89% of groups A, 100% of group B, and 100%" of group C.

Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate.

The efficacy and safety of three regimens of treatment for kala-azar (visceral leishmaniasis) with sodium stibogluconate were evaluated in a randomised clinical trial to ascertain the optimal